Bone Metastatic Pain Palliation in A Modified Rat Bone Cancer Pain Model Using Re-188-Hedp Therapy

Congjin Liu,Jieping Song,Yingqiliang Mao,Xingdang Liu
2015-01-01
Journal of Nuclear Medicine
Abstract:1199 Objectives This study investigated Re-188-1-hydroxyethylidene-1,1-diphosphonate (Re-188-HEDP) as a therapeutic agent for the palliation of bone metastatic pain in a modified rat bone metastatic pain model. Methods Syngeneic Walker 256 mammary gland carcinoma cells were injected into the female rats9 right tibia medullary cavity via intercondylar eminence to make the models (Day 1). Equal amount phosphate buffer solution (PBS) were injected to the control group (Group A). The bone cancer pain models were devided into three groups (Group B: non-radiotherapy group, Group C: high dose of radiotherapy group which were injected 37MBq of 188Re-HEDP for 150g weight through caudal vein, and Group D: low dose group of 18.5MBq/150g). The radiopharmaceutical were given to Group C and D on Day 15. Mechanical allodynia of both left and right back legs was evaluated by a von Frey filament test every 2 days from Day 1 to Day 31. Results The threshold value of mechanical allodynia of right back legs descended early on 2 days later after model making in all groups, but in Group B, C, D the threshold descended much more fast than that in Group A in the following up. Slight hyperpathia occured in all the left back legs. The pain threshold of right back legs ascended very early to 2 days after radiotherapy in both the two therapy groups, Group C and D. In Group C hyperpathia continued to improve in following up. But in Group D there was a significant fall of pain threshold after 10 days9 ascending. There was no difference of hyperpathia improvment during the first 10 days between the two therapy groups. Conclusions The modified rat bone metastatic pain model could be an effective animal model for radiopharmaceutical therapy research in palliation of bone cancer pain. 188Re-HEDP could be a useful therapeutic agent for the palliation of metastatic bone pain and the effect of palliation may be dose related. Research Support Project 81201113 supported by NSFC.
What problem does this paper attempt to address?